Sara L. Tolliday, PharmD, RPh

Anxiety disorders create social and economic burdens as the availability of effective anxiolytic treatments are low.

Pharmacists are ideally positioned within communities to identify patients struggling with perinatal depression.

Larotrectinib was the first drug to receive accelerated FDA approval for patients of all ages based on a common molecular marker, independent of tissue origin for targeted therapy.

Olaparib was the first PARP inhibitor to be developed and has been the most studied.

The FDA initially approved regorafenib for chemorefractory metastatic colorectal cancer and unresectable gastrointestinal stromal tumor in 2012.

Common and debilitating, the mental health condition is often underdiagnosed and undertreated.

AQP-modulating agent discovery has proved challenging, but many powerful AQP3 permeating molecules have been identified.

A recent study proved community pharmacies are model settings for skin cancer prevention education in rural communities with insufficient access to health care services.

Pharmacists’ vast health care knowledge and community accessibility makes them ideal patient liaisons.